查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433625

氣喘治療藥物市場規模、佔有率和趨勢分析報告：按藥物類別、產品、給藥途徑、地區和細分市場預測，2024-2030年

Asthma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Anti- inflammatory, Bronchodilators), By Product (Inhalers, Nebulizers), By Routeof Administration (Oral, Inhaled), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

氣喘藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球氣喘治療市場規模將達到379.1億美元，2024年至2030年複合年成長率為5.3%。

氣喘盛行率的不斷上升，加上採用生技藥品作為治療嚴重氣喘的長期治療選擇，預計將為該市場提供利潤豐厚的成長機會。根據《世界過敏雜誌》發表的統計數據，2014年5月，大約有3億人患有氣喘，隨著許多人轉向不健康的飲食和久坐的生活方式，這一數字正在迅速增加。

此外，主要品牌藥物如順爾寧（Singulair）、Advair等的專利在預測期內到期將加劇學名藥競爭，這將對未來幾年氣喘藥物市場的成長產生負面影響。相反，生技藥品的引入導致氣喘藥物領域的市場佔有率擴大，並且預計在預測期內將繼續擴大。

與傳統的藥物處方模式相反，對治療嚴重氣喘的個人化醫療方法的需求不斷成長，預計將推動未來氣喘藥物市場的出現。此外，採用感測器技術和內建無線通訊系統的加壓計量吸入器和智慧吸入器等技術先進產品的開發預計將在未來七年進一步推動氣喘治療市場的成長。

氣喘藥物市場報告亮點

  • 由於針對嚴重氣喘的經濟實惠且創新的生技藥品的推出，預計發炎藥物類別將在預測期內呈現快速成長。另一個好處是人們越來越認知到生物製藥和單株抗體的好處，預計這將在未來幾年擴大市場。
  • 乾粉吸入器 (DPI) 預計將成為成長最快的細分市場，因為這些設備的採用率越來越高，因為它們比其他吸入器具有更高的臨床效率。乾粉吸入器 (DPI) 由於其比其他吸入器更高的臨床效率而得到越來越多的採用。這些好處導致了快速採用率和市場滲透率的提高。
  • 越來越多的人選擇替代治療方法，例如吸入組合藥物來治療氣喘，預計將為該市場提供未來的成長機會。
  • 氣喘治療市場的主要企業包括阿斯特捷利康公司、飛利浦醫療保健公司、梯瓦製藥工業有限公司、葛蘭素史克公司、賽諾菲安萬特公司、CareFusion Corporation、Sunovion Pharmaceuticals, Inc.、勃林格殷格翰有限公司、羅氏診斷公司，例子包括默克公司
  • 為了獲得競爭優勢，市場領導正在專注於引進技術先進的設備以及新的和改進的生技藥品。在氣喘藥物領域，有近100個新分子正在開發中，且產品管線非常豐富，因為製造商專注於開發個人化治療方法。上述因素共同將在不久的將來加強該行業的成長。
  • 例如，Teva Pharmaceutical Industries Ltd.的Cinquil、羅氏的Lebrikizumab（III期）、AB Science的Mastinib（II/III期）和GlaxoSmithKline Plc的Bosatria（III期）等藥物分子正處於臨床研究試驗的開發階段。 。它位於如果在預測期內上市，這種垂直整合的癌症藥物預計將獲得發展動能。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章氣喘藥物市場：變數、趨勢、範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 氣喘藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章：氣喘藥物市場：藥物類別估計與趨勢分析

  • 2023年及2030年藥品類別市場佔有率
  • 細分儀表板
  • 按藥物類別分類的全球氣喘藥物市場展望
  • 2018年至2030年市場規模、預測與趨勢分析

第5章氣喘治療藥物市場：產品估算與趨勢分析

  • 2023年及2030年產品市場佔有率
  • 細分儀表板
  • 全球氣喘藥物市場展望（按產品）
  • 2018年至2030年市場規模、預測與趨勢分析

第6章氣喘治療藥物市場：給藥途徑預估及趨勢分析

  • 2023 年及 2030 年給藥途徑市場佔有率
  • 細分儀表板
  • 按給藥途徑分類的全球氣喘藥物市場展望
  • 2018年至2030年市場規模、預測與趨勢分析

第7章氣喘治療藥物市場：區域估計與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商形勢
    • Teva Pharmaceutical Industries Ltd
    • GSK plc
    • Merck &Co., Inc.
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • Sanofi
    • Koninklijke Philips NV
    • BD
    • Covis Pharma
Product Code: 978-1-68038-936-4

Asthma Therapeutics Market Growth & Trends:

The global asthma therapeutics market size is expected to reach USD 37.91 billion by 2030, expanding at a CAGR of 5.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of asthma coupled with the adoption of biologics as a long-term treatment option to treat the severe form of asthma is expected to offer this market with lucrative growth opportunities. According to the statistics published by the World Allergy Journal, in May 2014, patients suffering from asthma registered around 300 million and the number is expected to soar due to a large number of individuals inclining towards unhealthy dietary habits and sedentary lifestyles.

In addition, patent expiration of branded drugs, such as Singulair, Advair and other major drugs during the forecast period has led to a stiff generic competition, which will negatively impact the asthma therapeutics market growth in the coming years. On the contrary, the introduction of biologics is accruing towards the increasing market share of the asthma therapeutics segment, and is anticipated to continue during the forecast period.

The enhanced demand for personalized medicine approach as opposed to the conventional medication prescription pattern for treatment of severe asthma is anticipated to aid the emergence of asthma therapeutics market in the future. In addition, development of technologically advanced products, such as pressurized metered dose inhalers and smart inhalers, equipped with sensor technology and inbuilt wireless communication system is further expected to propel the asthma therapeutics market growth in the next seven years.

Asthma Therapeutics Market Report Highlights:

  • The anti-inflammatory drug class is expected to exhibit rapid growth of over the forecast period owing to the introduction of affordable and innovative biologics targeting the severe asthma condition. In addition, the awareness gained pertaining to the benefits rendered by the biologics and monoclonal antibodies is anticipated to exhibit an upward shift in the market expansion in the coming years.
  • The dry powder inhalers (DPIs) are expected to be the fastest growing segment due to the increasing adoption of these devices because of their high clinical efficiency than other inhalers. They are able to deliver both, small and large-sized drug components and dispense specialty engineered molecules. These related merits have spiked the adoption rates thereby contributing towards the risen market penetration.
  • Rising number of individuals opting for alternative treatment options, such as inhaled fixed-dose combination drugs for asthma medication is anticipated to serve this market with future growth opportunities.
  • Some of the key players operating in the asthma therapeutics market include AstraZeneca Plc, Philips Healthcare, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Roche Diagnostics, and Merck& Co., Inc.
  • Market leaders are focusing on the introduction of technologically advanced devices and novel, improved biologics to gain a competitive advantage. The asthma therapeutics segment has a very strong pipeline as there are almost 100 novel molecules that are in the development phase and manufacturers are focusing on the development of personalized medication. The aforementioned factors collectively strengthen the industry growth in the near future.
  • For instance, drug molecules, such as Cinquil by Teva Pharmaceutical Industries Ltd., Lebrikizumab by Roche (Phase III), Mastinib by AB Science (Phase II/III), and Bosatria by GlaxoSmithKline Plc (Phase III), are in the development stage undergoing clinical research trials. Their commercial availability during the forecast period is expected to provide a boost to this vertical.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Product
    • 1.2.3. Route of Administration
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for Primary Interviews in North America
      • 1.4.5.2. Data for Primary Interviews in Europe
      • 1.4.5.3. Data for Primary Interviews in Asia Pacific
      • 1.4.5.4. Data for Primary Interviews in Latin America
      • 1.4.5.5. Data for Primary Interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Product outlook
    • 2.2.3. Rout of administration outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Asthma Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing incidence of asthma
      • 3.2.1.2. Emergence of novel biologics
      • 3.2.1.3. Rising awareness programs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Patent expiration of branded drugs
      • 3.2.2.2. Regulatory challenges
  • 3.3. Asthma Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Asthma Therapeutics Market by Drug Class Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Anti- inflammatory
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Bronchodilators
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3. Combination Therapy
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Asthma Therapeutics Market: Product Estimates & Trend Analysis

  • 5.1. Product Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Asthma Therapeutics Market by Product Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Inhalers
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.1.2. Dry Powder
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.1.3. Metered Dose
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.1.4. Soft Mist
      • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.2. Nebulizers
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Asthma Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Route of Administration Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Asthma Therapeutics Market by Route of Administration Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Oral
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2. Inhaled
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Asthma Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6. Europe
    • 7.6.1. Germany
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.2. UK
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.4. South Korea
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.5. Australia
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Teva Pharmaceutical Industries Ltd
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. GSK plc
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Merck & Co., Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. F. Hoffmann-La Roche Ltd
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. AstraZeneca
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Boehringer Ingelheim International GmbH
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Sanofi
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Koninklijke Philips N.V.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. BD
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Covis Pharma
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America asthma therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 3 North America asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 4 North America asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 5 North America asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 6 U.S. asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 7 U.S. asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 8 U.S. asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 9 Canada asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 10 Canada asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 11 Canada asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 12 Europe asthma therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 13 Europe asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 14 Europe asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 15 Europe asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 16 Germany asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 17 Germany asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 18 Germany asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 19 UK asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 20 UK asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 21 UK asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 22 France asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 23 France asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 24 France asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 25 Italy asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 26 Italy asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 27 Italy asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 28 Spain asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 29 Spain asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 30 Spain asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 31 Denmark asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 32 Denmark asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 33 Denmark asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 34 Sweden asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 35 Sweden asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 36 Sweden asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 37 Norway asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 38 Norway asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 39 Norway asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 40 Asia Pacific asthma therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 41 Asia Pacific asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 42 Asia Pacific asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 43 Asia Pacific asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 44 China asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 45 China asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 46 China asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 47 Japan asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 48 Japan asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 49 Japan asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 50 India asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 51 India asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 52 India asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 53 South Korea asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 54 South Korea asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 55 South Korea asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 56 Australia asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 57 Australia asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 58 Australia asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 59 Thailand asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 60 Thailand asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 61 Thailand asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 62 Latin America asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 63 Latin America asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 64 Latin America asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 65 Brazil asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 66 Brazil asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 67 Brazil asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 68 Mexico asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 69 Mexico asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 70 Mexico asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 71 Argentina asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 72 Argentina asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 73 Argentina asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 74 MEA asthma therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 75 MEA asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 76 MEA asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 77 MEA asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 78 South Africa asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 79 South Africa asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 80 South Africa asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 81 Saudi Arabia asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 82 Saudi Arabia asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 83 Saudi Arabia asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 84 UAE asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 85 UAE asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 86 UAE asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 87 Kuwait asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 88 Kuwait asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 89 Kuwait asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary Interviews in North America
  • Fig. 5 Primary Interviews in Europe
  • Fig. 6 Primary Interviews in APAC
  • Fig. 7 Primary Interviews in Latin America
  • Fig. 8 Primary Interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Asthma therapeutics market: market outlook
  • Fig. 14 Asthma therapeutics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Asthma therapeutics market driver impact
  • Fig. 20 Asthma therapeutics market restraint impact
  • Fig. 21 Asthma therapeutics market strategic initiatives analysis
  • Fig. 22 Asthma therapeutics market: Drug class movement analysis
  • Fig. 23 Asthma therapeutics market: Drug class outlook and key takeaways
  • Fig. 24 Anti-inflammatory market estimates and forecast, 2018 - 2030
  • Fig. 25 Bronchodilators inhalers market estimates and forecast, 2018 - 2030
  • Fig. 26 Combination therapy inhalers market estimates and forecast, 2018 - 2030
  • Fig. 27 Asthma therapeutics market: Product movement analysis
  • Fig. 28 Asthma therapeutics market: Product outlook and key takeaways
  • Fig. 29 Inhalers market estimates and forecast, 2018 - 2030
  • Fig. 30 Dry powder inhalers market estimates and forecast, 2018 - 2030
  • Fig. 31 Metered dose inhalers market estimates and forecast, 2018 - 2030
  • Fig. 32 Soft mist inhalers market estimates and forecast, 2018 - 2030
  • Fig. 33 Nebulizers market estimates and forecast, 2018 - 2030
  • Fig. 34 Asthma therapeutics market: Route of administration movement analysis
  • Fig. 35 Asthma therapeutics market: Route of administration outlook and key takeaways
  • Fig. 36 Oral market estimates and forecasts, 2018 - 2030
  • Fig. 37 Inhaled market estimates and forecasts,2018 - 2030
  • Fig. 38 Others market estimates and forecasts, 2018 - 2030
  • Fig. 39 Global asthma therapeutics market: Regional movement analysis
  • Fig. 40 Global asthma therapeutics market: Regional outlook and key takeaways
  • Fig. 41 Global asthma therapeutics market shares and leading players
  • Fig. 42 North America market share and leading players
  • Fig. 43 Europe market share and leading players
  • Fig. 44 Asia Pacific market share and leading players
  • Fig. 45 Latin America market share and leading players
  • Fig. 46 Middle East & Africa market share and leading players
  • Fig. 47 North America: SWOT
  • Fig. 48 Europe SWOT
  • Fig. 49 Asia Pacific SWOT
  • Fig. 50 Latin America SWOT
  • Fig. 51 MEA SWOT
  • Fig. 52 North America, by country
  • Fig. 53 North America
  • Fig. 54 North America market estimates and forecasts, 2018 - 2030
  • Fig. 55 U.S. key country dynamics
  • Fig. 56 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 57 Canada key country dynamics
  • Fig. 58 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 59 Europe
  • Fig. 60 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 61 UK key country dynamics
  • Fig. 62 UK market estimates and forecasts, 2018 - 2030
  • Fig. 63 Germany key country dynamics
  • Fig. 64 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 65 France key country dynamics
  • Fig. 66 France market estimates and forecasts, 2018 - 2030
  • Fig. 67 Italy key country dynamics
  • Fig. 68 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 69 Spain key country dynamics
  • Fig. 70 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 71 Denmark key country dynamics
  • Fig. 72 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 73 Sweden key country dynamics
  • Fig. 74 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 75 Norway key country dynamics
  • Fig. 76 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 77 Asia Pacific
  • Fig. 78 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 79 China key country dynamics
  • Fig. 80 China market estimates and forecasts, 2018 - 2030
  • Fig. 81 Japan key country dynamics
  • Fig. 82 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 83 India key country dynamics
  • Fig. 84 India market estimates and forecasts, 2018 - 2030
  • Fig. 85 Thailand key country dynamics
  • Fig. 86 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 87 South Korea key country dynamics
  • Fig. 88 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 89 Australia key country dynamics
  • Fig. 90 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 91 Latin America
  • Fig. 92 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 93 Brazil key country dynamics
  • Fig. 94 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 95 Mexico key country dynamics
  • Fig. 96 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 97 Argentina key country dynamics
  • Fig. 98 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 99 Middle East and Africa
  • Fig. 100 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 101 South Africa key country dynamics
  • Fig. 102 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 103 Saudi Arabia key country dynamics
  • Fig. 104 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 105 UAE key country dynamics
  • Fig. 106 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 107 Kuwait key country dynamics
  • Fig. 108 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 109 Market share of key market players - Asthma therapeutics market